11,028 Shares in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Acquired by SG Americas Securities LLC

SG Americas Securities LLC acquired a new stake in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 11,028 shares of the biotechnology company’s stock, valued at approximately $39,000.

Several other institutional investors and hedge funds have also recently modified their holdings of ALDX. Ameritas Investment Partners Inc. purchased a new position in Aldeyra Therapeutics during the second quarter valued at $32,000. Tower Research Capital LLC TRC grew its position in shares of Aldeyra Therapeutics by 47,866.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,317 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 4,308 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Aldeyra Therapeutics in the first quarter worth about $57,000. UBS Group AG lifted its position in shares of Aldeyra Therapeutics by 256.0% in the first quarter. UBS Group AG now owns 6,408 shares of the biotechnology company’s stock worth $64,000 after buying an additional 4,608 shares in the last quarter. Finally, Graham Capital Management L.P. bought a new position in Aldeyra Therapeutics during the third quarter valued at approximately $68,000. Institutional investors own 59.71% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Aldeyra Therapeutics in a research report on Tuesday, April 2nd. StockNews.com raised shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, January 29th. Finally, Oppenheimer upgraded shares of Aldeyra Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 target price on the stock in a report on Wednesday, April 3rd.

Insider Buying and Selling

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc bought 309,847 shares of the company’s stock in a transaction on Wednesday, April 3rd. The stock was acquired at an average price of $4.09 per share, for a total transaction of $1,267,274.23. Following the completion of the transaction, the insider now directly owns 9,097,858 shares of the company’s stock, valued at $37,210,239.22. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc bought 309,847 shares of the firm’s stock in a transaction dated Wednesday, April 3rd. The stock was acquired at an average cost of $4.09 per share, for a total transaction of $1,267,274.23. Following the completion of the transaction, the insider now owns 9,097,858 shares in the company, valued at $37,210,239.22. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, insider Bruce Greenberg sold 13,201 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $3.41, for a total transaction of $45,015.41. Following the sale, the insider now directly owns 120,699 shares of the company’s stock, valued at $411,583.59. The disclosure for this sale can be found here. Insiders have bought 355,933 shares of company stock valued at $1,473,245 in the last ninety days. 7.30% of the stock is owned by company insiders.

Aldeyra Therapeutics Stock Performance

NASDAQ:ALDX opened at $3.86 on Monday. The firm has a market capitalization of $227.35 million, a PE ratio of -6.03 and a beta of 1.51. The stock’s fifty day moving average is $3.59 and its 200 day moving average is $3.25. Aldeyra Therapeutics, Inc has a fifty-two week low of $1.42 and a fifty-two week high of $11.97.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its earnings results on Thursday, March 7th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.13. Equities analysts forecast that Aldeyra Therapeutics, Inc will post -0.14 EPS for the current year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.